Comparison of C-reactive protein with distinct hyperinflammatory biomarkers in association with COVID-19 severity, mortality and SARS-CoV-2 variants.

Content Provider	Europe PMC
Author	Paranga, Tudorita Gabriela Pavel-Tanasa, Mariana Constantinescu, Daniela Plesca, Claudia Elena Petrovici, Cristina Miftode, Ionela-Larisa Moscalu, Mihaela Cianga, Petru Miftode, Egidia Gabriela
Copyright Year	2023
Abstract	C-reactive protein (CRP) has been one of the most investigated inflammatory-biomarkers during the ongoing COVID-19 pandemics caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The severe outcome among patients with SARS-CoV-2 infection is closely related to the cytokine storm and the hyperinflammation responsible for the acute respiratory distress syndrome and multiple organ failure. It still remains a challenge to determine which of the hyperinflammatory biomarkers and cytokines are the best predictors for disease severity and mortality in COVID-19 patients. Therefore, we evaluated and compared the outcome prediction efficiencies between CRP, the recently reported inflammatory modulators (suPAR, sTREM-1, HGF), and the classical biomarkers (MCP-1, IL-1β, IL-6, NLR, PLR, ESR, ferritin, fibrinogen, and LDH) in patients confirmed with SARS-CoV-2 infection at hospital admission. Notably, patients with severe disease had higher serum levels of CRP, suPAR, sTREM-1, HGF and classical biomarkers compared to the mild and moderate cases. Our data also identified CRP, among all investigated analytes, to best discriminate between severe and non-severe forms of disease, while LDH, sTREM-1 and HGF proved to be excellent mortality predictors in COVID-19 patients. Importantly, suPAR emerged as a key molecule in characterizing the Delta variant infections.
Page Count	22
Journal	Frontiers in Immunology
Volume Number	14
PubMed Central reference number	PMC10302717
PubMed reference number	37388734
e-ISSN	16643224
DOI	10.3389/fimmu.2023.1213246
Language	English
Publisher	Frontiers Media S.A.
Publisher Date	2023-06-14
Access Restriction	Open
Rights License	This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Copyright © 2023 Paranga, Pavel-Tanasa, Constantinescu, Plesca, Petrovici, Miftode, Moscalu, Cianga and Miftode
Subject Keyword	COVID-19 CRP suPAR s-TREM-1 HGF biomarkers disease severity mortality
Content Type	Text
Resource Type	Article
Subject	Immunology Immunology and Allergy